Abstract: The present invention relates to a competitive inhibitor of the binding of the protein Bcl-2 L10 to the ligand binding domain of at least one of the IP3R receptors, for its use in the treatment of cancers, the cells of which express the protein Bcl-2 L10.

Abstract: The present invention concerns a method for generating a pattern of light, this method comprising the following steps: a) emitting an input laser pulse (P1), b) deflecting the input laser pulse (P1) by a first deflector (22) to obtain a first laser pulse, c) deflecting the first laser pulse (P3) by a second deflector (24) to obtain a second laser pulse (P4), and d) focusing the pulse (P4) by an optical element characterized in that: —the first deflector (22) shapes the first laser pulse (P3) according to a first function, —the second deflector (24) shapes the second laser pulse (P4) according to a second function, and—the first function f(x) and the second function g(y) are computed and/or optimized to obtain the desired pattern of light.

Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.

Abstract: The present invention relates to a calcineurin inhibitor for use in the treatment of a lesional vestibular disorder.

Abstract: Dendrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors. The invention concerns a kit-of-parts comprising 5?-hydroxy-6?-[2-(1H-imidazol-4-yl)ethylamino]cholestan-3?-ol (Dendrogenin A) or a pharmaceutically acceptable salt thereof and an antineoplastic agent for use in the treatment of cancer. Furthermore, the invention concerns Dendrogenin A or a pharmaceutically acceptable salt thereof for use for treating a chemoresistant cancer.

Abstract: The invention relates to a novel method for the synthesis of an erythrocyte protein, in which said protein is synthesized in an acellular system for the production of proteins, in the presence of at least one detergent which is non-ionic, of liposomes or of nanodiscs. The invention also relates to compositions comprising the proteins produced in this way.

Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.

Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non-invasive methods for determining the quality of an embryo by determining the level of the cell free nucleic acids or miR-29a or let7-b in the nucleic acid extract from a follicular fluid sample.

Abstract: The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.

Abstract: The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.

Abstract: The present invention concerns a CDC25A phosphatase inhibitor for use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering or having suffered from cancer.

Abstract: The present invention relates to a neutralizing antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralizes the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralizing antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.

Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meani

Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.

Abstract: The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will no

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.

Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.

Abstract: The present application relates to an inhibitor of fusion between a viral membrane from an enveloped virus and a cell membrane, where the viral membrane comprises a fusion mediating protein including a C-terminal peptide. The inhibitor comprises the C-terminal peptide of the fusion mediating protein from an enveloped virus and tocopherol or a derivative or pharmaceutically acceptable salt thereof attached to the C-terminal peptide. Also disclosed is a pharmaceutical composition including the inhibitor as well as methods of inhibiting viral fusion, blocking viral spread, and preventing or treating viral infection, with the inhibitor or pharmaceutical composition.

Abstract: The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperon activity and/or is not capable of binding to best-shock protein 70 (HSP70) and/or to beat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP110. Such a mutated heat-shock protein 110 can be used (i) in methods for proposing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers.